{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:48:53Z","timestamp":1757544533107,"version":"3.37.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":608,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>In the United States, more than 1.1 million individuals are infected with the human immunodeficiency virus (HIV). These patients exhibit a high frequency of coinfections with other hepatotropic viruses and ongoing fibrosis, leading to cirrhosis and liver-related mortality. Etiologies of liver disease include viral hepatitis coinfections, drug-related hepatotoxicity, fatty liver disease, and direct and indirect effects from HIV infection, including increased bacterial translocation, immune activation, and presence of soluble proteins, that modulate the hepatic cytokine environment. New treatments for hepatitis C virus (HCV) using direct-acting agents appear viable, though issues related to intrinsic toxicities and drug-drug interactions remain. Recent research suggests that acute HCV infection, unrecognized hepatitis D infection, and hepatitis E may all represent emergent areas of concern. Antiretroviral agents, including those used in recent years, may represent risk factors for hepatic injury and portal hypertension. Key issues in the future include systematic implementation of liver disease management and new treatment in HIV-infected populations with concomitant injection drug use, alcohol use, and low socioeconomic status.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26638","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T18:48:19Z","timestamp":1375296499000},"page":"307-317","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Human immunodeficiency virus and liver disease forum 2012"],"prefix":"10.1097","volume":"59","author":[{"given":"Kenneth E.","family":"Sherman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-33-20250213","first-page":"25","article-title":"The changing epidemiology of liver disease in HIV patients.","volume":"15","author":"Soriano","year":"2013","journal-title":"AIDS Rev"},{"key":"R2-33-20250213","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10461-008-9509-7","article-title":"Running in place: implications of HIV incidence estimates among urban men who have sex with men in the United States and other industrialized countries.","volume":"13","author":"Stall","year":"2009","journal-title":"AIDS Behav"},{"key":"R3-33-20250213","first-page":"86","article-title":"Continuum of HIV care: differences in care and treatment by sex and raceethnicity in the United States.","volume":"15","author":"Hall","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"R4-33-20250213","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1097\/QAD.0b013e32834bbb90","article-title":"Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.","volume":"25","author":"Soriano","year":"2011","journal-title":"AIDS"},{"key":"R5-33-20250213","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3201\/eid1803.111278","article-title":"Hepatitis E virus infection in HIV-infected persons.","volume":"18","author":"Crum-Cianflone","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"R6-33-20250213","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3201\/eid\/1706.101067","article-title":"Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland.","volume":"17","author":"Kenfak-Foguena","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"R7-33-20250213","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1743-422X-8-171","article-title":"Hepatitis E virus infection in HIV-infected patients with elevated serum transaminases levels.","volume":"8","author":"Sellier","year":"2011","journal-title":"Virol J"},{"key":"R8-33-20250213","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkp446","article-title":"Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.","volume":"65","author":"Vispo","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R9-33-20250213","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.qai.0000221683.44940.62","article-title":"Severe liver disease associated with prolonged exposure to antiretroviral drugs.","volume":"42","author":"Maida","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-33-20250213","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/cid\/cit001","article-title":"Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients.","volume":"56","author":"Vispo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R11-33-20250213","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1053\/j.gastro.2011.07.051","article-title":"Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury.","volume":"141","author":"Davern","year":"2011","journal-title":"Gastroenterology"},{"key":"R12-33-20250213","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"key":"R13-33-20250213","doi-asserted-by":"crossref","first-page":"e1001194","DOI":"10.1371\/journal.pmed.1001194","article-title":"CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.","volume":"9","author":"Young","year":"2012","journal-title":"PLoS Med"},{"key":"R14-33-20250213","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.2012.7844","article-title":"Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIVHCV.","volume":"308","author":"Limketkai","year":"2012","journal-title":"JAMA"},{"key":"R15-33-20250213","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavireffects on HIV-1 replication and resistance.","volume":"356","author":"McMahon","year":"2007","journal-title":"N Engl J Med"},{"key":"R16-33-20250213","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1086\/383151","article-title":"Nucleoside analogues and mitochondrial toxicity.","volume":"38","author":"Fleischer","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R17-33-20250213","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/j.1365-2036.2011.04648.x","article-title":"The incidence, predictors and management of anaemia and its association with virological response in HCV HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.","volume":"33","author":"Butt","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-33-20250213","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2334-9-203","article-title":"Hepatic profile analyses of tipranavir in phase II and III clinical trials.","volume":"9","author":"Mikl","year":"2009","journal-title":"BMC Infect Dis"},{"key":"R19-33-20250213","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00428-010-1004-7","article-title":"The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV.","volume":"458","author":"Schiano","year":"2011","journal-title":"Virchows Arch"},{"key":"R20-33-20250213","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/QAD.0b013e3283389e26","article-title":"Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings.","volume":"24","author":"Vispo","year":"2010","journal-title":"AIDS"},{"key":"R21-33-20250213","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.23136","article-title":"Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virushepatitis C virus.","volume":"50","author":"Macias","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"R22-33-20250213","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/infdis\/jis926","article-title":"Pathogenesis of accelerated fibrosis in HIVHCV co-infection.","volume":"207","author":"Lin","year":"2013","journal-title":"J Infect Dis"},{"key":"R23-33-20250213","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/j.gastro.2008.01.005","article-title":"HIV increases HCV replication in a TGF-beta1-dependent manner.","volume":"134","author":"Lin","year":"2008","journal-title":"Gastroenterology"},{"key":"R25-33-20250213","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1074\/jbc.M110.168286","article-title":"HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB.","volume":"286","author":"Lin","year":"2011","journal-title":"J Biol Chem"},{"key":"R26-33-20250213","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2010.07.042","article-title":"HIV infection increases HCV-induced hepatocyte apoptosis.","volume":"54","author":"Jang","year":"2011","journal-title":"J Hepatol"},{"key":"R27-33-20250213","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2008.03.022","article-title":"Human immunodeficiency virus-related microbial translocation and progression of hepatitis C.","volume":"135","author":"Balagopal","year":"2008","journal-title":"Gastroenterology"},{"key":"R28-33-20250213","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis.","volume":"13","author":"Seki","year":"2007","journal-title":"Nat Med"},{"key":"R29-33-20250213","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/COH.0b013e32834bd2b7","article-title":"Hepatocellular carcinoma in HIV hepatitis C virus.","volume":"6","author":"Puoti","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"R30-33-20250213","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2007.06.010","article-title":"Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.","volume":"47","author":"Brau","year":"2007","journal-title":"J Hepatol"},{"key":"R31-33-20250213","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2008.11.018","article-title":"Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study.","volume":"50","author":"Salmon-Ceron","year":"2009","journal-title":"J Hepatol"},{"key":"R32-33-20250213","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.2011.396","article-title":"Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007.","volume":"305","author":"Shiels","year":"2011","journal-title":"JAMA"},{"key":"R33-33-20250213","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7326\/0003-4819-153-7-201010050-00008","article-title":"Age at cancer diagnosis among persons with AIDS in the United States.","volume":"153","author":"Shiels","year":"2010","journal-title":"Ann Intern Med"},{"key":"R34-33-20250213","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update.","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"R35-33-20250213","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/0003-4819-158-9-201305070-00604","article-title":"HIV, Age, and the severity of hepatitis C virus-related liver Disease: a cohort study.","volume":"158","author":"Kirk","year":"2013","journal-title":"Ann Intern Med"},{"key":"R36-33-20250213","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma.","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"R38-33-20250213","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/QAD.0b013e3283366602","article-title":"Survival of HIV-infected patients with compensated liver cirrhosis.","volume":"24","author":"Tuma","year":"2010","journal-title":"AIDS"},{"key":"R39-33-20250213","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/lt.21735","article-title":"The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.","volume":"15","author":"Murillas","year":"2009","journal-title":"Liver Transpl"},{"key":"R40-33-20250213","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1600-6143.2010.03070.x","article-title":"Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients.","volume":"10","author":"Coffin","year":"2010","journal-title":"Am J Transplant"},{"key":"R41-33-20250213","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/lt.23411","article-title":"Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection.","volume":"18","author":"Terrault","year":"2012","journal-title":"Liver Transpl"},{"key":"R42-33-20250213","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2893.2006.00824.x","article-title":"Response rates to pegylated interferon and ribavirin in HCVHIV coinfection: a research synthesis.","volume":"14","author":"Shire","year":"2007","journal-title":"J Viral Hepat"},{"key":"R43-33-20250213","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.23020","article-title":"Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.","volume":"50","author":"Berenguer","year":"2009","journal-title":"Hepatology"},{"key":"R44-33-20250213","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.","volume":"169","author":"Sulkowski","year":"2013","journal-title":"Ann Intern Med"},{"key":"R45-33-20250213","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"R46-33-20250213","first-page":"1551","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection (vol 365, pg 1014, 2011).","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"R47-33-20250213","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection.","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"R48-33-20250213","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/cid\/cir882","article-title":"Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.","volume":"54","author":"Thomas","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R53-33-20250213","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/08897070802218661","article-title":"Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse.","volume":"29","author":"Khalsa","year":"2008","journal-title":"Subst Abus"},{"key":"R54-33-20250213","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/j.1572-0241.2008.01877.x","article-title":"Management of chronic hepatitis C in veterans: the potential of integrated care models.","volume":"103","author":"Ho","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R55-33-20250213","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2893.2009.01080.x","article-title":"Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents.","volume":"16","author":"Grebely","year":"2009","journal-title":"J Viral Hepat"},{"key":"R56-33-20250213","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","article-title":"Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.","volume":"20","author":"Mehta","year":"2006","journal-title":"AIDS"},{"key":"R57-33-20250213","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1155\/2011\/810108","article-title":"Physicians attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.","volume":"25","author":"Myles","year":"2011","journal-title":"Can J Gastroenterol"},{"key":"R58-33-20250213","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2013.03.008","article-title":"Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.","volume":"59","author":"Marco","year":"2013","journal-title":"J Hepatol"},{"key":"R59-33-20250213","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/cis921","article-title":"Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.","volume":"56","author":"Page","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R60-33-20250213","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R61-33-20250213","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/0003-4819-152-11-201006010-00003","article-title":"Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.","volume":"152","author":"Lucas","year":"2010","journal-title":"Ann Intern Med"},{"issue":"Suppl 4","key":"R62-33-20250213","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1086\/522556","article-title":"Interrelation between psychiatric disorders and the prevention and treatment of HIV infection.","volume":"45","author":"Treisman","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26638","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201401000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T02:02:13Z","timestamp":1739412133000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201401000-00033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26638","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}